Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(13%)

Phase Distribution

Ph not_applicable

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

N/ANon-phased studies

4(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(2)

Other(2)

Detailed Status

Completed4

unknown2

Withdrawn1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

N/A

Trials by Phase

N/A4 (100.0%)

Trials by Status

withdrawn113%

terminated113%

completed450%

unknown225%

Recent Activity

0 active trials

Showing 5 of 8

completednot_applicable

Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor

NCT02842333

completednot_applicable

Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer

NCT02838381

completednot_applicable

Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable

NCT02818907

completednot_applicable

Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer

NCT02817178

withdrawn

Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma

NCT03942900

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT02842333Not Applicable

Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor

Completed

NCT02838381Not Applicable

Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer

Completed

NCT02818907Not Applicable

Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable

Completed

NCT02817178Not Applicable

Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer

Completed

NCT03942900

Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma

Withdrawn

NCT04836793

COVID-19-Study of Immune Responses Following Vaccination Against SARS-CoV-2

Unknown

NCT02844491

Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B

Terminated

NCT04365322

Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)

Unknown

All 8 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 8